Heidelberg Pharma AG (XTER:HPHA) Change In Receivables : €-0.66 Mil (TTM As of Feb. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Change In Receivables?

Heidelberg Pharma AG's change in receivables for the quarter that ended in Feb. 2024 was €-0.93 Mil. It means Heidelberg Pharma AG's Accounts Receivable increased by €0.93 Mil from Nov. 2023 to Feb. 2024 .

Heidelberg Pharma AG's change in receivables for the fiscal year that ended in Nov. 2023 was €-0.87 Mil. It means Heidelberg Pharma AG's Accounts Receivable increased by €0.87 Mil from Nov. 2022 to Nov. 2023 .

Heidelberg Pharma AG's Accounts Receivable for the quarter that ended in Feb. 2024 was €0.27 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Heidelberg Pharma AG's Days Sales Outstanding for the three months ended in Feb. 2024 was 19.16.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Heidelberg Pharma AG's liquidation value for the three months ended in Feb. 2024 was €22.05 Mil.

Heidelberg Pharma AG Change In Receivables Historical Data

The historical data trend for Heidelberg Pharma AG's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Change In Receivables Chart

Heidelberg Pharma AG Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

Change In Receivables

Get a 7-Day Free Trial

-0.79

-0.10

0.06

-0.87

Heidelberg Pharma AG Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Change In Receivables	Get a 7-Day Free Trial															-1.14	1.22	0.32	-1.26	-0.93

Heidelberg Pharma AG Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.66 Mil.

Heidelberg Pharma AG (XTER:HPHA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Heidelberg Pharma AG's Days Sales Outstanding for the quarter that ended in Feb. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.266	/	1.267	*	91
=	19.16

2. In Ben Graham's calculation of liquidation value, Heidelberg Pharma AG's accounts receivable are only considered to be worth 75% of book value:

Heidelberg Pharma AG's liquidation value for the quarter that ended in Feb. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	32.65	-	16.552	+	0.75 * 0.266	+	0.5 * 11.497
=	22.05

Heidelberg Pharma AG Change In Receivables Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Heidelberg Pharma AG (XTER:HPHA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

HPHA:Germany HPHA:Germany HPHA:Germany

Address

Gregor-Mendel-Street 22, Ladenburg, DEU, 68526

Website

https://www.heidelberg-pharma.com

Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.

Executives

Prof. Dr. Andreas Pahl

Board of Directors

Heidelberg Pharma AG (XTER:HPHA) Headlines

No Headlines